Artikkelit
More information about Artikkelit
How should individuals with positive autoimmune T1D autoantibodies be monitored over time?
Individuals who screen positive for ≥1 autoimmune islet cell antibodies need periodic medical monitoring, which includes regular assessments of blood glucose and HbA1c levels. You can also educate them about symptoms of diabetes, diabetic ketoacidosis (DKA), and provide psychosocial support to prepare them for a possible clinical diagnosis for type 1 diabetes (T1D).1
Early detection of autoimmune type 1 diabetes could reduce the risk of diabetic ketoacidosis
Delay in screening for autoimmune type 1 diabetes (T1D) can increase the risk of diabetic ketoacidosis (DKA) at diagnosis—a critical complication that is potentially life-threatening and may result in long-term poor glycemic control and neurological complications.1,2 By identifying autoimmune T1D early, you can significantly lower the risk of DKA at diagnosis.3,4
Real-life stories from people living with autoimmune T1D
The progression of autoimmune type 1 diabetes (T1D) is gradual, often detectable months or even years before symptoms arise.1–3 Through proactive screening, we can identify the condition well in advance.3 Meet our ambassadors living with autoimmune T1D and discover the risk factors to look out for when considering who to screen.
Does your patient have an existing autoimmune condition? Check for autoimmune type 1 diabetes!
Individuals living with other associated autoimmune diseases like celiac disease or autoimmune thyroid disease, are at an increased risk of developing autoimmune type 1 diabetes (T1D) and should be appropriately screened.1-6
Can autoimmune type 1 diabetes be detected years before symptom onset?
Autoimmune type 1 diabetes (T1D) is a progressive disease in which the decline in beta cell function usually begins months or sometimes years before clinical symptoms are observed.1–3 You can identify such patients at risk of developing autoimmune T1D before clinical symptoms are noticed by you or your patient.3
Autoimmune Type 1 Diabetes
The Type 1 Diabetes (T1D) field is evolving.
Recognition of the presymptomatic stages in T1D is growing.1-4
The clinical benefits of early detection of T1D are being highlighted.3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.1,2
▼EFLUELDA - korkea-annoksinen influenssarokote
▼ Tähän lääkevalmisteeseen kohdistuu lisäseuranta.
